<DOC>
	<DOCNO>NCT00195416</DOCNO>
	<brief_summary>To identify follow problem question respect safety effectiveness Enbrel post-marketing period require Korea Food Drug Administration ( KFDA ) 's regulation . 1 . Unknown adverse reaction , especially serious adverse reaction 2 . Change incidence adverse reaction routine drug use 3 . Factors may affect safety drug 4 . Factors may affect effectiveness drug</brief_summary>
	<brief_title>Study Investigating Enbrel Treatment Ankylosing Spondylitis</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Adults : Severe ankylose spondylitis ( AS ) patient respond adequately previous therapy Patients know hypersensitivity Enbrel component product Patients sepsis risk sepsis Patients active infection include chronic localized infection tuberculosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Ankylosing Spondylitis</keyword>
</DOC>